The identified EPO inhibitors might possibly contribute to the development of novel lead compounds as starting points for the development of new medicines for the treatment of inflammatory and neurodegenerative diseases caused by eosinophilic disorders such as bronchial asthma, inflammatory bowel diseases or ALS. Here, EPO is linked to neurodegenerative disease.